Kaituo Pharmaceutical announced that its independently developed KX-826 has recently received approval from the International Cosmetic Ingredient Naming Committee for naming and has been officially named Methylpyridinyl Fluoromethoxybenzonitrile Dimethyloxothiooxoimidazolidine. The naming is conducive to the company launching functional cosmetics with KX-826 as the main ingredient to the global market.
开拓药业：KX-826获得INCI命名批准
KX-826 of Kaituo Pharmaceutical has received INCI approval for nomenclature.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.